Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Next Previous
X
Search
Drug Profile

Zimberelimab - Arcus Biosciences/Guangzhou Gloria Biosciences/Taiho Pharmaceutical

Alternative Names: AB 122; GLS 010; GS-0122; WBP 3055; YUTUO

Latest Information Update: 16 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WuXi Biologics
  • Developer Arcus Biosciences; Gilead Sciences; Guangzhou Gloria Biosciences; Memorial Sloan-Kettering Cancer Center; Strata Oncology; Taiho Pharmaceutical; UCLAs Jonsson Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer; Hodgkin's disease
  • Phase III Gastrointestinal cancer; Non-small cell lung cancer
  • Phase II Biliary cancer; Liposarcoma; Liver cancer; Malignant melanoma; Rectal cancer
  • Phase I/II Colorectal cancer; Pancreatic cancer; Solid tumours
  • No development reported Cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 08 Aug 2024 Arcus Biosciences completes enrolment from its Phase-III clinical trials in Gastrointestinal cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Lithuania, Spain, Hungary, USA (IV) (NCT05568095)
  • 29 Jul 2024 Compugen plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in USA in the fourth quarter of 2024 (Parenteral),
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top